EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark ALNYLAM was filed as Word mark on 08/09/2018 at the European Union Intellectual Property Office.
It was registered as a trademark on 01/10/2019.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 017941141 |
| Application date | August 9, 2018 |
| Publication date | October 3, 2018 |
| Entry date | January 10, 2019 |
| Expiration date | August 9, 2028 |
Trademark owner
675 West Kendall Street
02142 Cambridge
US
02142 Cambridge
US
Trademark representatives
1 bis rue de Pongerville
92000 Nanterre
FR
goods and services
5
Pharmaceutical preparations, namely, rna therapeutics for use in the treatment of cancer, hiv, hepatitis a, hepatitis b, influenza, measles, neurodegenerative diseases, transthyretin (ttr)-mediated amyloidosis (attr), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary attr amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis b virus infection, hepatitis d virus infection, chronic liver infection; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, hiv, hepatitis a, hepatitis b, influenza, measles, neurodegenerative diseases, transthyretin (ttr)-mediated amyloidosis (attr), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary attr amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis b virus infection, hepatitis d virus infection, chronic liver infection; pharmaceutical preparations, namely, rna therapeutics; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| June 20, 2023 | Change Representative, Published | ||
| December 2, 2022 | Transfer / Change of address, Published | ||
| March 10, 2021 | Change Representative, Published | ||
| January 27, 2021 | Change Representative, Published | ||
| October 18, 2018 | Transfer / Change of address, Registered |
ID: 11017941141